Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioHarvest Sciences ( (BHST) ) just unveiled an announcement.
BioHarvest Sciences has completed Stage 1 of a multi-stage development program to create a stable cell culture from a rare, endangered fragrance-producing plant used in the global perfume industry. Using its proprietary Botanical Synthesis Platform, the company replicated key scent molecules, including sesquiterpenes and chromones, with molecular profiles closely matching the original plant.
The achievement opens BioHarvest’s entry into the premium fragrance segment, estimated at about $23 billion within the broader $58.9 billion scents market, and targets a raw material whose premium grades sell for tens of thousands of dollars per kilogram. Under the agreement, BioHarvest retains 20% ownership of the compositions, supporting a royalty-driven model as it evolves from a traditional CDMO to a partner-focused development and manufacturing organization.
Backed by a prominent UAE-based investment group, the program is now moving to Stage 2, in which cell bank material will be scaled in liquid media to generate biomass for pre-commercial testing within six to nine months and industrial-scale production within 12 to 18 months. Management expects this project to serve as a template for further fragrance programs, indicating potential for a broader pipeline of sustainable, high-value fragrance ingredients and reinforcing BioHarvest’s positioning in premium, hard-to-source plant molecules.
The most recent analyst rating on (BHST) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial performance (ongoing net losses, negative operating/free cash flow, and elevated leverage) and bearish technicals (below key moving averages with negative MACD). The latest earnings call adds support via strong revenue growth, improving gross margins, and guidance pointing toward adjusted EBITDA breakeven, but valuation remains constrained by unprofitability and no dividend.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a botanical synthesis and sustainable plant-based molecule developer that operates a contract development and manufacturing (CDMO) business. The company focuses on producing rare, high-value plant-derived compounds at industrial scale for sectors such as fragrances, leveraging proprietary cell culture technology to avoid traditional cultivation and harvesting.
Average Trading Volume: 26,486
Technical Sentiment Signal: Buy
Current Market Cap: $96.73M
See more insights into BHST stock on TipRanks’ Stock Analysis page.